Robert L. DeJager - Concepedia

Author

Robert L. DeJager

University of Amsterdam

Also Known As

R DeJager, R. DeJager, R. Dejager, R. L. Dejager, Robert DeJager, Robert L. DeJager

Publications

315

Citations

H-Index

Concepts

All Affiliations

University of Amsterdam The University of Texas MD Anderson Cancer Center Automated Precision (United States)Memorial Sloan Kettering Cancer Center University of Alabama at Birmingham

About

Robert L. DeJager is an author at University of Amsterdam specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	144
2	Health Sciences	2	2	32
3	Gastroenterology	2	2	64
4	Biostatistics	1	1	19
5	Immunology	1	1	17

Robert L. DeJager

Publications

302

Citations

H-Index

Page 1

	Year	Citations
Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy Shreyaskumar Patel, Mary Louise Keohan, Muhammad Wasif Saif, Cancer	2006	57
The Muir-Torre Syndrome: A Disease of Sebaceous and Colonic Neoplasms Robert A. Schwartz, David Goldberg, Fayyaz Mahmood, Dermatology Tumoral PathologyFamily MembersMedicineSurgical PathologyHistopathology	1989	47
A Phase II study of intravenous exatecan mesylate (DX‐8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma Francisco J. Esteva, Edgardo Rivera, Massimo Cristofanilli, Cancer	2003	33
A new fiducial alignment system to overlay abdominal computed tomography or magnetic resonance anatomical images with radiolabeled antibody single-photon emission computed tomographic scans Yusuf E. Erdi, B. W. Wessels, Robert L. DeJager, Cancer	1994	32
Hepatitis after konyne administrationne administration Martin M. Oken, Lawrence A. Hootkin, Robert L. DeJager Digestive Diseases and Sciences Viral HepatitisHepatitisAcute Liver FailurePharmacotherapyMedicine	1972	21
A Phase I Randomized Study of Subcutaneous Adjuvant IL-2 in Combination with an Autologous Tumor Vaccine in Patients with Advanced Renal Cell Carcinoma Robert G. Fenton, Ronald G. Steis, Karen Madara, Journal of Immunotherapy	1996	20
Tumor activity confirmation and isodose curve display for patients receiving iodine-131-labeled 16.88 human monoclonal antibody Alev K. Erdi, B. W. Wessels, Robert L. DeJager, Cancer Tumor Activity ConfirmationOncologic ImagingPathologyPositron Emission TomographyNeuro-oncology	1994	19
Tumour localisation with 131I-labelled human IgM monoclonal antibody 16.88 in advanced colorectal cancer patients Epie Boven, Hidde J. Haisma, Herman Bril, European Journal of Cancer and Clinical Oncology Gastrointestinal OncologyMedicineImmunologyColorectal CancerPathology	1991	17
A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum Melanie Royce, Eric K. Rowinsky, Paulo M. Hoff, Investigational New Drugs Surgical OncologyGastrointestinal OncologyMedicineGastroenterologyPhase Ii Study	2003	17
Human IgM Monoclonal Antibody 16.88: Pharmacokinetics and Immunogenicity in Colorectal Cancer Patients Hidde J. Haisma, H. M. Pinedo, M. A. P. Kessel, JNCI Journal of the National Cancer Institute	1991	16

Page 1